

ESMO 2022 Industry Satellite Symposium

Is it time to raise the bar for **ALK+ NSCLC** patients?

Saturday 10th September, 2022 | 18:30–20:00 CEST
7.3.T- Toulouse Auditorium, Hall 7, Level 7.3,
Paris Expo Porte de Versailles, Paris, France



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology industry-sponsored symposium at ESMO 2022, entitled **“Is it time to raise the bar for ALK+ NSCLC patients?”**

We are delighted to be holding this **live, discussion-based, highly interactive symposium** where you will have the opportunity to participate in roundtable discussions.

During the symposium we will review the latest data and expectations for first-line ALK+ NSCLC therapy and discuss how to effectively manage adverse events during treatment. The faculty will also share perspectives on post-progression options in ALK+ NSCLC and discuss what the future might hold in this field.

My colleagues and I look forward to welcoming you for what promises to be an engaging and thought-provoking symposium.

Prof. Benjamin Solomon

Peter MacCallum Cancer Centre, Victoria, Australia

Program

Chair: **Prof. Benjamin Solomon (Australia)**

18:30–18:35	Welcome and introduction	Prof. Benjamin Solomon (Australia)
18:35–19:45	New data and updated expectations for first-line therapy	Prof. Benjamin Solomon (Australia)
	Managing AEs and keeping patients on treatment	Dr. Enriqueta Felip (Spain)
	What next? Options after progression on 2nd- and 3rd- generation TKIs	Prof. Nicolas Girard (France)
	The future of ALK+ NSCLC	Prof. Nicolas Girard (France)
	<i>Each presentation will be followed by panel discussion</i>	
19:45–19:55	Q&A	All faculty, facilitated by Prof. Benjamin Solomon (Australia)
19:55–20:00	Summary and close	Prof. Benjamin Solomon (Australia)



This meeting is organized and sponsored by Pfizer.
© Pfizer Inc.
July 2022. PP-UNP-GLB-0190.